Cyclerion discloses lawsuit challenging its asset sale; issues supplemental proxy disclosures

Cyclerion Therapeutics, Inc.

One lawsuit and five demand letters allege false/misleading proxy statement for the $8M + 10% stock sale to JW Celtics.
Supplemental disclosures: Stifel contacted 65 potential counterparties, 30 signed NDAs; no 'don't-ask-don't-waive' provisions.
Stifel's fee is $1.3M, mostly contingent on closing; $50k retainer credited. DCF shows Purchased Assets value range ($14M)-$4.4M.
CEO Peter Hecht will become CEO of Buyer Parent post-closing and received employment offer; no compensation talks before APA signing.
Non-risk-adjusted revenue projections for zagociguat and CY3018 added; risk-adjusted forecasts also disclosed for 2023-2045.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.